News on research and diagnostic developments in neuroscience.
The companies will develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
Assurex Health will use the MassArray system with its GeneSight Psychotropic pharmacogenetic test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The contract to Abbott is for the development of a traumatic brain injury assay. The estimated completion date of the contract is Oct. 23, 2019.